Genomic Prediction, a NYC-based developer of polygenic disease screening tests for improving IVF health outcomes, raised $4.5m through the sale of preferred stock.
The round was led by Nimble Ventures with participation from new investors PeopleFund and existing investors.
The company will use the new funding to expand its sales team and data science capability.
Led by CEO Laurent Christian Asker Melchior Tellier, Genomic Prediction translates genomic predictors of polygenic disease risk into disease prevention and improved clinical care in IVF. With its proprietary IVF genetic testing technologies, EPⓖT and ⓖSEQ, the system is able to simultaneously screen hundreds of single-gene disorders, and to score human embryos for multi-gene disease risk. This allows IVF couples and clinics to reduce the risk to the embryo of Type 1 Diabetes, Basal Cell Carcinoma, Ovarian Cancer, Heart Attack, Inflammatory Bowel Disease, and many more disorders.
This screening reduces disease incidence, protecting health from the start: in-embryo.
FinSMEs
31/01/2019